Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 9 findings · 3 reviews · Vascular

No studies found 3 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 22.2%Moderate 2 · 22.2%High 2 · 22.2%

Anticoagulant vs placebo or no intervention

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with distal DVT

Anticoagulant leads to higher clinically relevant non‐major bleeding ( compared with no intervention or placebo (high certainty).

1 finding from 1 review

Extended prophylaxis vs another VTE extended prophylaxis

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism

VTE extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingf compared with another VTE extended prophylaxis (moderate certainty).

1 finding from 1 review

Extended prophylaxis vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism

Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).

1 finding from 1 review

Vitamin K antagonists vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants (chosen at investigators' discretion) vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Heparin vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

DOAC vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).

1 finding from 1 review

DOAC vs heparin

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ clinically relevant, non‐major Treatment duration 28 ‐ 42… compared with heparin (high certainty).

1 finding from 1 review